KR101031605B1 - Manufacturing method of culture extract of ceriporia lacerata for the therapy of diabetic diseases and culture extract of ceriporia lacerata using the same - Google Patents
Manufacturing method of culture extract of ceriporia lacerata for the therapy of diabetic diseases and culture extract of ceriporia lacerata using the same Download PDFInfo
- Publication number
- KR101031605B1 KR101031605B1 KR1020100112236A KR20100112236A KR101031605B1 KR 101031605 B1 KR101031605 B1 KR 101031605B1 KR 1020100112236 A KR1020100112236 A KR 1020100112236A KR 20100112236 A KR20100112236 A KR 20100112236A KR 101031605 B1 KR101031605 B1 KR 101031605B1
- Authority
- KR
- South Korea
- Prior art keywords
- ria
- culture
- sera
- lock
- extract
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 84
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 42
- 238000004519 manufacturing process Methods 0.000 title claims description 18
- 241001466515 Emmia lacerata Species 0.000 title abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 10
- 238000002560 therapeutic procedure Methods 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 39
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 30
- 239000008103 glucose Substances 0.000 claims abstract description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 claims abstract description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000009630 liquid culture Methods 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000002904 solvent Substances 0.000 claims abstract description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 15
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 229960003371 protocatechualdehyde Drugs 0.000 claims abstract description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims abstract description 10
- 235000000346 sugar Nutrition 0.000 claims abstract description 8
- 229920002472 Starch Polymers 0.000 claims abstract description 7
- 235000019698 starch Nutrition 0.000 claims abstract description 7
- 239000008107 starch Substances 0.000 claims abstract description 7
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims abstract description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims abstract description 5
- 235000019341 magnesium sulphate Nutrition 0.000 claims abstract description 5
- 235000019796 monopotassium phosphate Nutrition 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 239000002609 medium Substances 0.000 claims description 11
- 150000001299 aldehydes Chemical class 0.000 claims description 9
- 239000001963 growth medium Substances 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 6
- 241000123410 Ceriporia Species 0.000 claims description 4
- 235000013312 flour Nutrition 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 4
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 4
- 239000013028 medium composition Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 abstract description 4
- 235000010469 Glycine max Nutrition 0.000 abstract 1
- 244000068988 Glycine max Species 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 abstract 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 28
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 108010028144 alpha-Glucosidases Proteins 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 7
- 230000003178 anti-diabetic effect Effects 0.000 description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
- 102000004139 alpha-Amylases Human genes 0.000 description 5
- 108090000637 alpha-Amylases Proteins 0.000 description 5
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000000469 ethanolic extract Substances 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 229940024171 alpha-amylase Drugs 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- WLDWSGZHNBANIO-UHFFFAOYSA-N 2',5'-Dihydroxyacetophenone Chemical compound CC(=O)C1=CC(O)=CC=C1O WLDWSGZHNBANIO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 150000008131 glucosides Chemical class 0.000 description 3
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- LWFUFLREGJMOIZ-UHFFFAOYSA-N 3,5-dinitrosalicylic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O LWFUFLREGJMOIZ-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 229920005610 lignin Polymers 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- NEZJDVYDSZTRFS-ZIQFBCGOSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-phenoxyoxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=CC=C1 NEZJDVYDSZTRFS-ZIQFBCGOSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- HPYIIXJJVYSMCV-MGDXKYBTSA-N astressin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(N[C@@H](C)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@@H](CCCCNC(=O)CC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)=O)C(C)C)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CNC=N1 HPYIIXJJVYSMCV-MGDXKYBTSA-N 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 235000021316 daily nutritional intake Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000004482 other powder Substances 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/208—Fungi extracts
Abstract
Description
본 발명은 세리포리아 락세라타 ( Ceriporia lacerata )를 이용한 액체 배양 및 배양액 추출물의 제조방법, 이에 따른 세리포리아 락세라타 배양액 추출물, 상기 세리포리아 락세라타 배양액 추출물을 포함하는 당뇨병 질환의 예방 및 치료를 위한 약학 조성물 및 건강기능식품에 관한 것이다.
The present invention three other repositories Ria Rock Serra (Ceriporia lacerata) a method for producing a liquid culture, and the culture extracts using, whereby three reports Ria lock Sera other culture extract, the three reports Ria lock Sera other pharmaceutical compositions and functional food for the prevention and treatment of diabetic diseases, including culture liquid extract according It is about.
세리포리아 락세라타 ( ceriporia lacerata )는 백색 부후균의 일종으로 생태계에서 셀룰로오스, 헤미 셀룰로오스, 기타 다당류 및 글리세롤(glycerol) 등의 탄소원을 이용하기 위하여 리그닌 분해라는 공동대사(cometabolism)를 수행하는 것으로 알려져 있다. 또한, 목재 조직의 리그닌 부분을 신속하고 효율적으로 분해하는 것은 알려져 있으나 세리포리아 락세라타 의 항당뇨 효과에 대한 보고는 알려진 바가 없다. Three other repositories Ria Rock Serra (ceriporia lacerata ) is a type of white fungus known to perform cometabolism called lignin degradation in order to use carbon sources such as cellulose, hemicellulose, other polysaccharides, and glycerol in the ecosystem. In addition, the rapid lignin part of wood and the organization is efficiently decomposed known, but reports of anti-diabetic effect of the three repositories Ria Rock Sera other is not known.
당뇨병은 대표적인 성인성 질환으로 세계인구의 5%가 걸려있으며, 그로 인한 인명적, 경제적 손실은 실로 막대하다. 당뇨병(Diabetic mellitus)은 두가지 유형으로 분류되는데, 이중 인슐린 의존형인 Ⅰ형 당뇨병(insulin dependent diabetes, IDDM)은 혈액 내의 글루코즈 조절 호르몬인 인슐린의 분비 결핍으로 야기되는 것으로, 주로 10~20대의 젊은 연령층에서 발병되기 때문에 소아당뇨병이라 불리우기도 한다. 그리고, Ⅱ형 당뇨병(non-insulin dependent diabetes, NIDDM)은 주로 40대 이후에 발병되며, 우리 나라 당뇨병 환자의 대부분을 차지한다. Ⅰ형 당뇨병과는 달리 성인형 당뇨병이라 불리우며 발병 원인은 아직 명확히 밝혀져 있지 않으나, 유전적인 요인과 환경적 요소가 함께 관여되어 발생하는 것으로 알려졌다. Diabetes is a representative adult disease, affecting 5% of the world's population, resulting in huge human and economic losses. Diabetes mellitus is classified into two types, of which insulin dependent diabetes (IDDM) is caused by a deficiency of insulin, a glucose-regulating hormone in the blood, mainly in young people in their 10s to 20s. It is also called pediatric diabetes because it develops. In addition, type II diabetes (non-insulin dependent diabetes, NIDDM) occurs mainly after the age of 40, and occupies most of the diabetic patients in our country. Unlike type I diabetes, it is called adult-type diabetes and the cause of the disease is not clear yet, but it is known to be caused by genetic factors and environmental factors.
Ⅱ형 당뇨병의 병인으로 췌장베타세포에서 인슐린 분비의 장애와 표적세포에서 인슐린 작용의 결함(인슐린 저항성)이 모두 관찰되는데, 이 중 어떠한 변화가 일차적 중요성을 갖는지는 아직 확실치 않다.The etiology of type II diabetes has been observed in both pancreatic beta cells and in insulin secretion and in target insulin cells (insulin resistance).
당뇨병의 가장 흔한 합병증인 당뇨성 말초 신경증은 10년 이상 진행된 당뇨병의 50% 정도에서 그 증세를 보이기 시작한다. 그 초기 증상은 손, 특히 발의 감각 이상으로 시작되어 심한 통증이 계속되다가, 감각 상실과 함께 말초자율신경의 손상으로 혈류장애가 나타난다. 더 진행되면 통증이 없는 궤양과 감염이 나타나고 심한 경우 손상된 사지의 절단이 필요한 경우도 있으며 급성인 경우 패혈증을 유발하여 생명이 위독한 경우까지 갈 수 있는 심각한 합병증이다.Diabetic peripheral neuropathy, the most common complication of diabetes, begins to manifest in about 50% of diabetes over 10 years. The initial symptoms begin with paresthesia of the hands, especially the feet, and continue with severe pain, resulting in impaired sensation and impairment of the peripheral autonomic nerves resulting in blood flow disorders. Further progression may result in painless ulcers and infections, and in severe cases, amputation of the damaged limbs may be necessary, and acute complications can lead to sepsis and life-threatening cases.
당뇨병 말초신경증의 발생 기전은 많은 연구에도 불구하고 아직 확실치 않다. 치료 방법을 보면, 궁극적으로 말초신경증을 비롯한 여러 당뇨합병증의 치료제는 없다. 적극적인 혈당조절과 고지혈증, 고콜레스테롤, 과체중, 흡연 및 음주 등 위험인자의 제거가 합병증의 발생을 어느 정도 예방하거나 지연시키는 것으로 알려져 있지만, 일단 발생한 합병증을 치료하는 약물은 현재로서는 존재하지 않는다. 한편, 합병증의 발생을 지연하거나 예방할 수 있는 약물의 개발이 국내외 여러 연구기관에서 진행 중이지만 아직 임상에 쓰이는 것은 없다.
The mechanism of development of diabetic peripheral neuropathy is not yet clear despite many studies. In terms of treatment, there is ultimately no cure for many diabetic complications, including peripheral neuropathy. Active glycemic control and elimination of risk factors such as hyperlipidemia, high cholesterol, overweight, smoking and drinking have been known to prevent or delay the occurrence of complications to some extent, but there are no drugs to treat complications once they occur. On the other hand, the development of drugs that can delay or prevent the occurrence of complications are in progress at various research institutes at home and abroad, but there is no clinical use.
따라서, 부작용이 없으며 안전성이 확보된 천연 소재인 세리포리아 락세라타 를 이용하여, 당뇨병 질환의 예방 및 치료에 탁월한 효능이 있다고 알려진 프로토카테추알데히드(Protocatechualdehyde) 등을 대량으로 포함하고 있는 세리포리아 락세라타 배양액 추출물 제조방법에 대한 개발이 요구되고 있다.
Therefore, there are no side effects, the three repositories containing safety is ensured with natural materials in three repositories Ria Rock Sera other using, Prototype category weight aldehydes (Protocatechualdehyde), including known that the superior efficacy in the prevention and treatment of diabetes disease in bulk Leah has been developing the requirements for the preparation Rock Serra another culture extracts.
본 발명은 세리포리아 락세라타 균사체의 액체 배양액으로부터 얻은 동결 건조물을 추출용매로 추출하고, 이를 여과 및 농축하여 얻은 세리포리아 락세라타 균사체의 배양액 추출물(이하, ‘ 세리포리아 락세라타 배양액 추출물’이라 한다) 제조방법 및 이에 따른 세리포리아 락세라타 배양액 추출물을 제공하고자 한다.
The invention three reports Ria lock Sera other extract lyophilized product obtained from a liquid culture of the mycelium by extraction solvent, and was filtered and concentrated to three reports Ria lock Sera other culture extract of the mycelia (hereinafter referred to as "three lipoic Ria lock sera obtained other referred to as the culture extracts') to provide a manufacturing method and thus three repositories Ria Rock Sera other culture extracts.
본 발명은 당뇨병 치료에 효과가 있다고 알려진 프로토카테추알데히드(Protocatechualdehyde)와 같은 유효성분들의 함량을 높여, 당뇨병 질환에 대한 예방 및 치료 효과가 탁월한 세리포리아 락세라타 배양액 추출물의 제조방법 및 이에 따른 세리포리아 락세라타 배양액 추출물을 제공하고자 한다.
The invention increases the amount of validity those such as the protocol category weight aldehydes (Protocatechualdehyde) known to be effective in the treatment of diabetes, a method of preventing and three reports Ria therapeutic effects superior lock Sera other culture extract for diabetic disease and accordingly It is intended to provide a extract of Ceriporia laccerata culture.
본 발명은 바람직한 제1구현예로서 (S1) 세리포리아 락세라타 ( Ceriporia lacerata )의 균사체를 액체 배양하여 세리포리아 균사체 배양액을 제조하는 단계; (S2) 세리포리아 락세라타 균사체 배양액을 동결 건조시켜 분말화하는 단계; 및 (S3) 세리포리아 락세라타 균사체 배양액 분말을 물, 에탄올, 메탄올, 아세톤, 부탄올 및 에틸아세테이트로 이루어진 군에서 선택된 1종의 용매 또는 2종 이상의 혼합용매로 추출한 후 이를 여과하고 감압 농축하는 단계;를 포함하는 세리포리아 락세라타 배양액 추출물의 제조방법을 제공한다.
The present invention is preferred as the first embodiment (S1) comprising: a liquid culture to produce an aged lipoic Ria mycelium culture mycelia of three reports Ria lock Sera other (Ceriporia lacerata); (S2) comprising: a powdered freeze-dried three reports Ria lock Sera other mycelium culture liquid; And (S3) the three reports Ria lock Sera other that after the mycelium culture medium powder, extracted with water, ethanol, methanol, acetone, butanol and ethyl acetate, one solvent or two or mixture of two or more solvents selected from the group consisting of filtered and concentrated under reduced pressure It provides a method for producing a culture extract of the seriporia lac serrata comprising the step.
상기 구현예에 의한 세리포리아 락세라타 배양액 추출물의 제조방법에서, (S1) 단계에서의 액체 배양은 20℃~30℃에서 5~16일간 수행되는 것일 수 있다.
In the production method of the three reports Ria lock Sera other culture extract according to this embodiment, the liquid culture of the (S1) step can be performed 5-16 days at 20 ℃ ~ 30 ℃.
상기 구현예에 의한 세리포리아 락세라타 배양액 추출물의 제조방법에서, (S1) 단계에서의 액체 배양은 1~3 vvm(공기 부피/배지 부피/분)의 공기를 주입하면서 수행되는 것일 수 있다.
In the production method of the three reports Ria lock Sera other culture extract according to this embodiment, the liquid culture of the (S1) step can be carried out while injecting the air of 1 ~ 3 vvm (air volume / medium volume / minute) .
이때, 상기 액체배양을 위한 배지 조성물은 포도당 0.2~3중량%, 설탕 0.2~3중량%, 전분 0.2~4중량%, 대두분 0.2~3중량%, 황산마그네슘(MgSO4)0.05~0.1중량%, 인산이수소칼륨(KH2PO4) 0.05~0.1중량% 및 물 90~99중량%를 포함하는 것일 수 있다.
At this time, the medium composition for the culture of the liquid is 0.2 to 3% by weight of glucose, 0.2 to 3% by weight of sugar, 0.2 to 4% by weight of starch, 0.2 to 3% by weight of soy flour, magnesium sulfate (MgSO 4 ) 0.05 to 0.1% by weight , Potassium dihydrogen phosphate (KH 2 PO 4 ) It may be one containing 0.05 to 0.1% by weight and water 90 to 99% by weight.
상기 구현예에 의한 세리포리아 락세라타 배양액 추출물의 제조방법에서, (S2) 단계에서의 동결 건조는 48시간~72시간 동안 수행되는 것일 수 있다.
In the production method of the three reports Ria lock Sera other culture extract according to this embodiment, the freeze-dried at (S2) step may be performed for 48 hours ~ 72 hours.
상기 구현예에 의한 세리포리아 락세라타 배양액 추출물의 제조방법에서, (S3) 단계에서의 용매는 물 또는 50%(w/w)~80%(w/w)의 에탄올 수용액일 수 있다.
Solvent in the producing method of the three reports Ria lock Sera other culture extract according to this embodiment, (S3) step may be aqueous ethanol solution in water or 50% (w / w) ~ 80% (w / w).
상기 구현예에 의한 세리포리아 락세라타 배양액 추출물의 제조방법에서, (S3) 단계에서의 추출은 세리포리아 락세라타 분말에 대하여 20~50mL/g의 극성용매를 첨가하여 수행되는 것일 수 있다.
Be those in the production method of the three reports Ria lock Sera other culture extract according to this embodiment, the extraction in the (S3) phase, three reports Ria lock Sera performed by adding a polar solvent of 20 ~ 50mL / g with respect to the other powder have.
상기 구현예에 의한 세리포리아 락세라타 배양액 추출물의 제조방법에서, (S3) 단계에서의 추출은 20℃~30℃에서 5~7시간 동안 수행되는 것일 수 있다.
In the production method of the three reports Ria lock Sera other culture extract according to this embodiment, the extraction in the (S3) step may be performed for 5 to 7 hours at 20 ℃ ~ 30 ℃.
본 발명은 바람직한 제2구현예로서 상기의 제조방법에 의하여 제조된 세리포리아 락세라타 배양액 추출물을 제공한다.
The invention in a preferred second embodiment provides a three reports Ria lock Sera other culture extract produced by the method for producing the.
상기 제2구현예에 의한 세리포리아 락세라타 배양액 추출물은, 프로토카테추알데히드(Protocatechualdehyde)를 10~25㎍/g 포함하는 것일 수 있다.
The first three reports Ria lock Sera other culture extract according to the second embodiment, may be one which includes a protocol category weight aldehydes (Protocatechualdehyde) 10 ~ 25㎍ / g .
상기 제2구현예에 의한 세리포리아 락세라타 배양액 추출물은, 프로토카테추알데히드(Protocatechualdehyde)를 17~25㎍/g 포함하는 것일 수 있다.
The first three reports Ria lock Sera other culture extract according to the second embodiment, may be one which includes a protocol category weight aldehydes (Protocatechualdehyde) 17 ~ 25㎍ / g .
본 발명은 바람직한 제3구현예로서 상기의 세리포리아 락세라타 배양액 추출물을 포함하는 당뇨병 질환의 예방 및 치료용 약학 조성물을 제공한다.
The invention as a third preferred embodiment provides a pharmaceutical composition for the prevention and treatment of diabetic diseases, including three reports Ria lock Sera other culture extract of said.
본 발명은 바람직한 제4구현예로서 상기의 세리포리아 락세라타 배양액 추출물을 포함하는 건강기능식품을 제공한다.
The invention as a fourth embodiment provides a health functional food comprising a three reports Ria lock Sera other culture extract of said.
도 1은 본 발명의 바람직한 일 실시예에 따른 세리포리아 락세라타 배양액 추출물의 내당능 분석 결과를 나타낸 그래프이고,
도 2는 본 발명의 바람직한 일 실시예에 따른 세리포리아 락세라타 배양액 추출물을 투여한 동물모델의 시간 경과에 따른 혈당 수치 변화를 나타낸 그래프이다.1 is a graph showing the glucose tolerance analysis of the three reports Ria lock Sera other culture extract according to an embodiment of the present invention,
2 is a graph showing blood glucose levels changes over time of the administration of three reports Ria lock Sera other culture extract according to an embodiment of the present invention an animal model.
이하, 본 발명을 더욱 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명은 (S1) 세리포리아 락세라타 ( Ceriporia lacerata )의 균사체를 액체 배양하여 세리포리아 락세라타 균사체 배양액을 제조하는 단계; (S2) 세리포리아 락세라타 균사체 배양액을 동결 건조시켜 분말화하는 단계; 및 (S3) 세리포리아 락세라타 균사체 배양액 분말을 물, 에탄올, 메탄올, 아세톤, 부탄올 및 에틸아세테이트로 이루어진 군에서 선택된 1종의 용매 또는 2종 이상의 혼합용매로 추출한 후 이를 여과하고 감압 농축하는 단계;를 포함하는 세리포리아 락세라타 배양액 추출물의 제조방법을 제공한다.
The present invention (S1) three other repositories Ria Rock Serra (Ceriporia liquid culture of the mycelium of lacerata ) to prepare a culture medium of the seriporia laccerata mycelia; (S2) comprising: a powdered freeze-dried three reports Ria lock Sera other mycelium culture liquid; And (S3) the three reports Ria lock Sera other that after the mycelium culture medium powder, extracted with water, ethanol, methanol, acetone, butanol and ethyl acetate, one solvent or two or mixture of two or more solvents selected from the group consisting of filtered and concentrated under reduced pressure It provides a method for producing a culture extract of the seriporia lac serrata comprising the step.
상기 (S1) 단계에서의 세리포리아 락세라타 균사체 배양액은 세리포리아 락세라타 ( Ceriporia lacerata )의 균사체를 액체 배양한 것으로, 상기 액체배양을 위한 배지 조성물은 포도당 0.2~3중량%, 설탕 0.2~3중량%, 전분 0.2~4중량%, 대두분 0.2~3중량%, 황산마그네슘(MgSO4)0.05~0.1중량%, 인산이수소칼륨(KH2PO4) 0.05~0.1중량% 및 물 90~99중량%를 포함하는 것일 수 있다.The three reports Ria lock Sera other mycelium culture in (S1) phase, three reports Ria lock Sera other (Ceriporia lacerata ) mycelium liquid culture, the medium composition for the culture of the liquid is 0.2 to 3% by weight of glucose, 0.2 to 3% by weight of sugar, 0.2 to 4% by weight of starch, 0.2 to 3% by weight of soy flour, magnesium sulfate ( MgSO 4 ) 0.05 to 0.1% by weight, potassium dihydrogen phosphate (KH 2 PO 4 ) may be to include 0.05 to 0.1% by weight and water 90 to 99% by weight.
이때, 액체배양은 20℃~30℃에서 1~3 vvm(공기 부피/배지 부피/분)의 공기를 주입하면서 5~16일간 수행되는 것이 바람직하고, 25℃에서 10일간 수행되는 것이 균사체 증식이 가장 활발하고 외부다당류(exopolysacchraid) 함량이 많으므로 가장 바람직하다. At this time, the liquid culture is preferably carried out for 5 to 16 days while injecting 1 to 3 vvm (air volume / medium volume / minute) at 20 ℃ ~ 30 ℃, it is carried out at 25 ℃ 10 days is mycelial growth Most preferred because it is the most active and has a high content of exopolysacchraid.
보다 구체적으로는, 상기 (S1) 단계에서의 세리포리아 락세라타 균사체 배양액은 세리포리아 락세라타 모균주를 PDA 배지에서 2~3회 계대배양 후 우량종을 획득한 후에, PDB 배지를 사용하여 배양기에서 20~25℃의 항온을 유지하며 7~9일간 소규모 액체 배양 과정을 거친 균사체를 액체 배양한 것이 균사체 증식이 가장 활발하므로 더욱 바람직하다.
More specifically, the (S1) phase three reports Ria lock Sera other mycelium broth is then obtained a two or three times subculture after precipitation species three reports Ria lock Sera other parent strain on PDA medium, PDB medium in It is more preferable to maintain the constant temperature of 20 ~ 25 ℃ in the incubator and liquid culture of the mycelium after a small liquid culture process for 7-9 days because the mycelial growth is the most active.
그리고, (S2) 단계에서는 상기 (S1) 단계에서 제조된 세리포리아 락세라타 배양액을 동결 건조시켜 분말화한다. 상기의 동결건조는 세리포리아 락세라타 균사 배양액을 고온에서 건조시키는 경우 유효물질이 상당 부분 소멸될 수 있으므로 30℃ 이하의 저온, 바람직하게는 20℃~30℃의 온도에서 48시간~72시간 동안 수행되는 것이 바람직하다. 그리고, (S2) 단계에서의 동결건조시에는 일반적으로 사용되는 동결건조기 대신에 진공 동결건조기를 사용하는 것이 지표 물질 함량 변화가 최소화되므로 더욱 바람직하다.
And, (S2) phase, the three reports Ria lock Sera other culture solution prepared in the step (S1) phase and powdered by lyophilization. The freeze-dried and aged lipoic Ria lock Sera other mycelial culture the case of drying at a high temperature effective because material can be destroyed significantly lower temperature of below 30 ℃, preferably at a temperature of 20 ℃ ~ 30 ℃ 48 sigan ~ 72 sigan Is preferably carried out during the process. In the step of freeze-drying in step (S2), it is more preferable to use the vacuum lyophilizer instead of the lyophilizer which is generally used since the change of the indicator material content is minimized.
(S3) 단계에서는 (S2) 단계에서 얻은 세리포리아 락세라타 균사체 배양액 분말을 용매로 추출한 후 이를 여과하고 감압농축하여 본 발명에 따른 세리포리아 락세라타 배양액 추출물을 제조한다. 상기 용매는 물, 에탄올, 메탄올, 아세톤, 부탄올 및 에틸아세테이트로 이루어진 군에서 선택된 1종의 용매 또는 2종 이상의 혼합용매인 것이 바람직하다. 특히, 상기 추출용매는 물 또는 50wt%~80wt% 농도의 에탄올 수용액인 것이 In vitro 실험에서 항당뇨 효과가 가장 뛰어나기에 더욱 바람직하다.(S3) and the step (S2) and extracted three reports Ria lock Sera other powdered mycelium culture obtained in step with a solvent, and filtered to prepare a three reports Ria lock Sera other culture extract according to the present invention was concentrated under reduced pressure. The solvent is preferably one solvent or two or more mixed solvents selected from the group consisting of water, ethanol, methanol, acetone, butanol and ethyl acetate. In particular, the extraction solvent is water or 50wt% ~ 80wt% ethanol aqueous solution is more preferable because the antidiabetic effect is the most excellent in vitro experiments.
상기 세리포리아 락세라타 균사체 배양액 분말을 용매로 추출하는 경우, 상기 용매는 세리포리아 락세라타 균사체 배양액 분말에 대하여 20~50mL/g의 함량으로 첨가하는 것이 추출이 용이하므로 바람직하다. 그리고, 상기 세리포리아 락세라타 균사체 배양액 분말에 상기 용매를 첨가한 후에는 20℃~30℃의 온도에서 5~7시간 동안, 더욱 바람직하게는 25℃에서 6시간 동안 추출하는 것이 바람직하다. 그리고, 상기 추출액을 여과한 후 감압농축한다.
When extracted with the three reports Ria lock Sera other solvents to the culture mycelium powder, the solvent is preferable since it is easy to extract, which is added in an amount of 20 ~ 50mL / g with respect to the three reports Ria lock Sera other mycelium broth powder. And, after addition of the solvent in the three reports Ria lock Sera other mycelium broth powder it is desirable to extract for for 5 to 7 hours at a temperature of 20 ℃ ~ 30 ℃, at more preferably 25 ℃ 6 hours. The extract is filtered and concentrated under reduced pressure.
이와 같이 제조된 본 발명에 따른 세리포리아 락세라타 배양액 추출물은 당뇨병 등의 예방 및 치료에 효과가 있는 유효성분들의 함량이 현저히 높아, 당뇨병 질환에 대한 예방 및 치료 효과가 매우 뛰어나다. 더욱 구체적으로는, 본 발명에 따른 세리포리아 락세라타 배양액 추출물은 항당뇨 효능이 있다고 알려진 프로토카테추알데히드(Protocatechualdehyde)가 10~25㎍/g의 매우 높은 함량으로 포함되어 있다.
Thus, the three repositories Ria Rock Serra another culture extracts prepared in accordance with the present invention, the content validity of those that is effective in the prevention and treatment of diabetes increases significantly, the prevention and treatment of diabetes disease is very excellent. More specifically, there are three reports Ria lock Sera other broth extract is anti-diabetic efficacy protocol category weight aldehydes (Protocatechualdehyde) known to be in accordance with the present invention is contained in a very high content of 10 ~ 25㎍ / g.
본 발명은 또한, 본 발명에 따른 세리포리아 락세라타 배양액 추출물을 포함하는 당뇨병 질환의 예방 및 치료용 약학 조성물 및 건강기능식품을 제공한다.
The present invention also provides a three repositories Ria Rock Serra another culture extracts pharmaceutical for the prevention and treatment of diabetes and diseases compositions comprising the dietary supplement according to the present invention.
이하, 본 발명의 구성을 실시예를 통하여 보다 상세히 설명하나, 본 발명의 범위가 하기 실시예 및 실험예로 한정되는 것은 아니다.
Hereinafter, the configuration of the present invention in more detail through examples, but the scope of the present invention is not limited to the following examples and experimental examples.
실시예Example 1: One: 세리포리아Serifonia 락세라타Lakserata 배양액 제조 Culture Preparation
캐나다 온타리오주에서 채취한 자실체로부터 분리한 세리포리아 락세라타 모균주를 장기 보존된 균주의 생리활성도를 높이고 건강한 균주를 선발하기 위해 PDA 배지에서 2~3회 계대배양 후 우량종을 획득하였다. 그리고, PDB 배지를 사용하여 배양기에서 항온을 유지하며 7일간 소규모 액체 배양한 균사체를 스타터로 사용하였다.
After the increase the physiological activity of the three separated from the fruiting bodies collected in Ontario Repo Ria Rock Sera other long-term preservation strains the parent strain 2-3 in the PDA medium to starting a healthy strains times subculture to obtain a superior species. In addition, mycelium cultured in small liquid culture for 7 days was used as a starter while maintaining constant temperature in the incubator using PDB medium.
그리고, 포도당 1.8중량%, 설탕 1중량%, 전분 1.1중량%, 대두분 1중량%, 황산마그네슘(MgSO4) 0.05중량%, 인산이수소칼륨(KH2PO4) 0.05중량% 및 물 95중량%를 포함하는 액체배양 배지를 121℃에서 20분간 멸균한 후, 이 배지를 이용하여 700L 발효조에서 공기를 3 vvm(공기 부피/배지 부피/분)으로 주입하면서 상기 세리포리아 락세라타를 25℃에서 10일간 액체 배양함으로써 세리포리아 락세라타 배양액을 제조하였다. Then, 1.8% by weight of glucose, 1% by weight of sugar, 1.1% by weight of starch, 1% by weight of soy flour, 0.05% by weight of magnesium sulfate (MgSO 4 ), 0.05% by weight of potassium dihydrogen phosphate (KH 2 PO 4 ) and 95% by weight of water After sterilizing the liquid culture medium containing 20% at 121 ° C. for 20 minutes, the medium was infused with 3 vvm (air volume / medium volume / min) in a 700L fermenter using the medium. by 10 days in liquid culture ℃ was prepared in three reports Ria lock Sera other medium.
또한, 진공 동결건조기를 이용하여 25℃의 저온에서 상기 세리포리아 락세라타 배양액을 72시간 동안 동결건조시켜 분말화하였다.In addition, the three sera lipoic Ria lock the other culture medium at a low temperature of 25 ℃ using a vacuum freeze-dryer was powdered by lyophilization for 72 hours.
그리고, 상기 세리포리아 락세라타 배양액 분말 3g에 100 mL의 70wt% 에탄올 수용액을 첨가하고 25℃에서 6시간 동안 추출하였다. 상기 추출액을 여과한 후 감압농축함으로써 세리포리아 락세라타 배양액 추출물을 제조하였다.
In addition, the sera were three reports Ria lock other addition of 70wt% aqueous ethanol solution of 100 mL in the culture medium and extracted from the powder 3g 25 ℃ for 6 hours. The extract was filtered and concentrated under reduced pressure to prepare a extract of Ceriporia laccerata culture.
실시예Example 2: 2: 세리포리아Serifonia 락세라타Lakserata 배양액 추출물의 제조 Preparation of culture extract
세리포리아 락세라타 배양액 분말 3g에 증류수를 100 mL의 양으로 첨가한 것을 제외하고는 실시예 1과 동일한 방법으로 제조함으로써 세리포리아 락세라타 배양액 추출물을 얻었다.
Three lipoic Ria lock Sera other by making the distilled water to the culture as a powder 3g in the same manner as in Example 1 except that the addition in an amount of 100 mL to obtain a three reports Ria lock Sera other culture extract.
실험예Experimental Example
1: One:
InIn
vitroin vitro
에서의 항 당뇨 활성 평가Of antidiabetic activity in
실험예Experimental Example 1-1: α- 1-1: α- 글루코시다제Glucosidase (α-(α- GlucosidaseGlucosidase ) 저해 활성Inhibitory activity
시료의 α-글루코시다제 저해 활성은 α-글루코시다제가 p-니트로페닐(p-nitrophenyl, pNP) 글루코시드(glucoside)의 글루코시드 부분을 기질로 인식하여, pNP와 글루코시드를 효소 반응으로 끊어주고, 여기에서 끊어져 나온 pNP의 양을 405nm에서 흡광도를 측정하여 나타내었다. The α-glucosidase inhibitory activity of the sample indicates that the α-glucosidase recognizes the glucoside portion of the p-nitrophenyl (pNP) glucoside as a substrate, and the pNP and the glucoside are separated by an enzymatic reaction. The amount of pNP broken out here was measured and measured at 405 nm.
즉, 실시예 1 및 실시예 2에서 제조한 추출물을 농도별로 제조하기 쉽게 동결건조시켜 분말로 제조한 후, 증류수를 이용하여 농도별(5mg/mL, 10mg/mL, 50mg/mL, 100mg/mL, 150mg/mL)로 희석한 각각의 희석액 100㎕를 0.75U/mL의 α-글루코시다제 효소액 50㎕ 및 50mM의 인산칼륨 버퍼(buffer)(pH 6.5)와 혼합한 후, 2mM의 p-니트로페닐 α-D-글루코피라노시드(pNPG) 250㎕을 가하여 37℃에서 30분간 반응시켰다. 상기 반응액을 0.1M 탄산나트륨(Na2CO3) 500㎕로 반응 정지시킨 후, 405nm에서 흡광도를 측정하였으며 양성 대조군(비교예)으로는 아카보즈(acarbose)를 사용하였다.
That is, the extracts prepared in Examples 1 and 2 were lyophilized to be easily prepared for each concentration, and then prepared into powder, and then distilled water was used for each concentration (5 mg / mL, 10 mg / mL, 50 mg / mL, 100 mg / mL). 100 μl of each dilution diluted with 150 mg / mL) was mixed with 50 μL of 0.75 U / mL of α-glucosidase enzyme solution and 50 mM potassium phosphate buffer (pH 6.5), followed by 2 mM p-nitro. 250 µl of phenyl α-D-glucopyranoside (pNPG) was added and reacted at 37 ° C for 30 minutes. The reaction solution was quenched with 500 μl of 0.1 M sodium carbonate (Na 2 CO 3 ), the absorbance was measured at 405 nm, and acarbose was used as a positive control (comparative example).
α-글루코시다제는 소장의 솔가장자리 막(brush-border membrane)에 존재하는 소화효소로서 이당류나 다당류 형태의 탄수화물이 소화 흡수되기 위한 상태인 단당류로 가수분해하는 역할을 한다. α-글루코시다제 저해제는 탄수화물 식이 후 혈당상승을 억제할 수 있다. 세리포리아락세라타 균사체 배양액의 70wt% 에탄올 추출물(실시예 1)과 물 추출물(실시예 2)의 α-글루코시다제 저해 활성을 측정한 결과는 표 1과 같다. 물 추출물(실시예 2)의 IC50 값은 28.90mg/mL, 70wt% 에탄올 추출물(실시예 1)의 IC50 값은 101.00mg/mL로 물 추출물(실시예 2)의 활성이 훨씬 우수하였다.
α-glucosidase is a digestive enzyme present in the brush-border membrane of the small intestine, and hydrolyzes into monosaccharides in which disaccharides and polysaccharide forms of carbohydrate are digested and absorbed. α-glucosidase inhibitors can inhibit blood glucose levels after carbohydrate diets. The results of measuring the α-glucosidase inhibitory activity of the 70 wt% ethanol extract (Example 1) and the water extract (Example 2) of the culture medium of the three S. liporia lacserata mycelium are shown in Table 1. IC 50 of water extract (Example 2) Value is 28.90 mg / mL, IC 50 of 70 wt% ethanol extract (Example 1) The value was 101.00 mg / mL and the activity of the water extract (Example 2) was much better.
실험예Experimental Example 1-2: α-아밀라제(α- 1-2: α-amylase (α- AmylaseAmylase ) 저해 활성Inhibitory activity
시료의 판크레아틴(Pancreatin) 유래의 α-아밀라제에 대한 저해 활성은 전분(Starch)을 기질로 하여 측정하였다. 실시예 1 및 실시예 2에서 제조한 추출물을 농도별로 제조하기 쉽게 동결건조시켜 분말로 제조한 후, 증류수를 이용하여 농도별(50mg/mL, 100mg/mL, 200mg/mL)로 희석한 각 추출물 25㎕에 0.7U/mL의 α-아밀라제 효소액 200㎕ 및 50mL 인산칼륨 버퍼(pH 6.5) 100㎕를 혼합하여 37℃에서 10분간 반응시킨 후 1.0% 전분 200㎕를 혼합하여 37℃에서 5분간 반응시키고 48mM DNS(3,5-dinitrosalicylic acid) 용액을 200㎕ 첨가하였다. 100℃에서 15분간 가열하여 발색시키고 충분히 냉각시킨 후 증류수를 가하여 교반한 다음, 540nm에서 흡광도를 측정하였다. 양성 대조군으로는 아카보즈를 사용하였다.Inhibitory activity of α-amylase derived from Pancreatin from the samples was measured using starch as a substrate. The extracts prepared in Examples 1 and 2 were lyophilized to make them easy to prepare by concentration, and then prepared into powders, and then each extract diluted by concentration (50 mg / mL, 100 mg / mL, 200 mg / mL) with distilled water. 200 μl of 0.7 U / mL α-amylase enzyme solution and 100 μl of 50 mL potassium phosphate buffer (pH 6.5) were mixed at 25 ° C. for 10 minutes, and 200 μl of 1.0% starch was mixed for 5 minutes at 37 ° C. Then, 200 μl of a 48 mM DNS (3,5-dinitrosalicylic acid) solution was added. After heating at 100 ° C. for 15 minutes to develop color and cooling sufficiently, distilled water was added and stirred, and then the absorbance was measured at 540 nm. Acarbose was used as a positive control.
판크레아틴 유래의 α-아밀라제에 대한 세리포리아 락세라타 배양액 추출물의 저해 활성을 측정한 결과는 하기 표 2와 같다. 70wt% 에탄올 추출물(실시예 1)과 물 추출물(실시예 2)의 IC50 값은 각각 102.44mg/mL, 89.65mg/mL로 나타나 물 추출물의 저해 효과가 조금 더 높은 것으로 나타났다. 이러한 결과로 α-글루코시다제 저해 활성과 유사한 결과이며 물로 추출할 경우 당뇨병에 효과가 좋은 지표 물질들이 많이 추출된다고 예상할 수 있다.
Result the plate three reports Ria lock inhibitory activity of the sera other culture extract for α- amylase derived from a measure of the creatine is shown in Table 2 below. IC 50 of 70 wt% ethanol extract (Example 1) and water extract (Example 2) The values were 102.44 mg / mL and 89.65 mg / mL, respectively, indicating that the inhibitory effect of the water extract was slightly higher. These results are similar to the α-glucosidase inhibitory activity, and when extracted with water, it can be expected that many indicator substances which are effective for diabetes are extracted.
실험예Experimental Example 2: 경구 2: oral 내당능Glucose tolerance 검사( inspection( OGTTOGTT , , OralOral GlucoseGlucose ToleranceTolerance TestTest )를 통한 Through) 세리포리아Serifonia 락세라타Lakserata 배양액 추출물의 Of culture extract 항당뇨Antidiabetic 효과 effect
12시간 이상 절식시킨 정상 래트(rat)(4주령)의 공복시 혈당을 측정한 다음, 실시예 2에서 제조한 세리포리아 락세라타 배양액 추출물을 희석하기 쉽게 동결건조시켜 분말로 만든 후 200mg/kg의 농도가 되도록 증류수로 희석시킨 시료를 각 군별로 다섯 마리씩 먼저 경구투여하였다. 이때, 대조군에는 생리식염수를 동량으로 투여하였다. 그리고, 대조군을 제외한 다른 군에게는 40wt% 농도의 포도당을 2g/kg bw 농도로 경구투여한 다음 각각 30, 60, 90, 120분에 미정맥으로부터 채혈하고 혈당변화를 관찰하였다. 각 시점의 혈당 증가치를 계산하여 혈당증가곡선을 구하여, 도 1에 나타내었다.
12 hours or more fasted that normal rats (rat) after (4 weeks old) was measured fasting glucose, and then, the second embodiment to easily lyophilized three reports Ria diluting the lock Sera other culture extract produced in the made into powder 200mg / kg Diluted with distilled water so that the concentration of 5 samples in each group was orally administered first. At this time, the control group was administered the same amount of physiological saline. In addition, except for the control group, 40wt% glucose was orally administered at a concentration of 2g / kg bw, and blood was collected from the vein at 30, 60, 90, and 120 minutes, respectively, and blood glucose change was observed. The blood glucose increase curve was calculated by calculating the increase in blood glucose at each time point, and is shown in FIG. 1.
래트의 내당능 검사는 도 1에 나타낸 바와 같이, 포도당 투여 30분 후에 모든 실험군에서 최고 혈당치를 나타내다가 시간이 경과할수록 혈당치가 감소되었다. 그리고, 시료 처리군에 비하여 시료를 처리하지 않고 포도당만 투여한 대조군에서 가장 높은 혈당을 나타내었고, 60분 이후부터는 실시예 2의 추출물을 투여한 군에서 혈당 감소치가 컸으나, 120분 후에는 모든 군에서 거의 공복전의 수준으로 혈당이 감소되었다. 따라서, 실시예 2의 추출물은 혈당 상승 억제 효과를 보이는 것으로 생각된다.
As shown in FIG. 1, the glucose tolerance test of rats showed the highest blood glucose level in all experimental groups after 30 minutes of glucose administration, and the blood glucose level decreased with time. In addition, compared to the sample treatment group, the control group administered with glucose only showed the highest blood sugar level without treating the sample, and after 60 minutes, the blood glucose reduction was greater in the group administered with the extract of Example 2, but after 120 minutes in all groups Glucose was reduced to almost fasting levels at. Therefore, the extract of Example 2 is considered to have a blood sugar synergistic inhibitory effect.
실험예Experimental Example 3: 동물모델을 이용한 3: using animal models 세리포리아Serifonia 락세라타Lakserata 배양액 추출물의 Of culture extract 항당뇨Antidiabetic 효과 검증 Effect verification
실험 동물 사육Breeding experimental animals
실험 동물은 평균 체중이 140±3.2g인 Sprague-Dawley계 수컷 흰쥐로서, 각 실험군마다 8마리씩 총 24마리를 구입하여 실내온도 23±2℃, 습도 60±5%, 명암주기 12시간의 환경조건에서 적응시키기 위해 시중에서 구입한 일반 배합사료(Purina Co., Korea)로 1주간 예비사육한 후 2주간 실험을 실시하였다.
The experimental animals were Sprague-Dawley male rats with an average body weight of 140 ± 3.2g, and 24 rats of 8 rats were purchased for each experimental group, and the environmental conditions were 23 ± 2 ℃, 60 ± 5% humidity, and 12 hours light cycle. In order to adapt to the preliminary breeding for 1 week with commercial commercial feed (Purina Co., Korea) purchased for 2 weeks experiment was carried out.
정상 쥐의 당뇨 유발Diabetes induction in normal rats
실험적인 제1형 당뇨 유발은 췌장의 β-세포를 선택적으로 파괴시킨다고 알려진 스트렙토조토신(streptozotocin; STZ, Sigma Chemical Co., St. Louis, MO, USA)을 0.01M 시트르산(citrate) 버퍼(pH 4.5)에 용해시켜 60mg/kg을 복강 내로 주사하였다. 당뇨병 발생은 STZ 투여 24시간 후 꼬리 정맥으로부터 채혈하여 공복 시 혈당이 200mg/dL 이상인 동물을 실험에 사용하였다.
실험군의Experimental 분류 Classification
실험군은 당뇨 유발 없이 정상 식이를 공급한 정상대조군(NC)과 당뇨 유발후 정상식이를 공급한 당뇨대조군(DM), 당뇨 치료 효과를 보기 위해서 당뇨 유발 후 2주간 실시예 2에서 제조한 세리포리아 락세라타 배양액 추출물을 동결건조시켜 분말로 제조한 후 200mg/kg의 농도로 희석하여 경구 투여한 당뇨치료군(DM-water)의 3군으로 분류하였다.
The test group three manufactured after diabetic to view after the normal control (NC) and diabetic supplies the normal diet without diabetic normal diet a diabetic control group (DM), diabetic treatment effect supplying the
체중, 식이 측정Body weight, dietary measure
모든 동물에 대하여 STZ 투여 개시 직전에 1회, STZ 투여 후와 실시예 2에서 제조한 세리포리아 락세라타 배양액 추출물 투여 후 매주 1회씩, 그리고 부검 당일 체중을 측정하였다. 한편, 사육 케이지 별로 매주 1회씩 일정량의 식이를 공급하고 익일 같은 시간에 사료의 잔량을 측정하여, 일일 평균 식이 섭취량(g/day)을 산출하였다.
A one-time, after the administration of STZ as in Example 2. After three reports Ria lock Sera other culture extract produced in a week administered once, and the day of autopsy on body weight immediately before the start of STZ administration were determined for all animals. On the other hand, by feeding a certain amount of diet once a week for each breeding cage and measuring the remaining amount of feed at the same time the next day, the average daily dietary intake (g / day) was calculated.
STZ로 당뇨 유발된 쥐에 실시예 2에서 제조한 세리포리아 락세라타 배양액 추출물을 경구투여하면서 2주간 사육한 동물의 체중 변화를 하기 표 3에 나타내었다. 정상군(NC)은 시간경과에 따라 체중이 지속적으로 증가하는 반면, 당뇨군(DM)의 경우 STZ에 의한 영향으로 체중이 감소하였다. 한편, 당뇨치료군(DM-Water)에서는 체중이 정상군보다는 감소하였으나, DM군에 비해서는 높은 체중을 보였다.While oral administration to a three reports Ria lock Sera other culture extract prepared in Example 2 on the diabetic mice induced by STZ to the weight change of the animal breeding two weeks are shown in Table 3 below. In the normal group (NC), the weight was continuously increased over time, while in the diabetic group (DM), the weight was decreased due to the effect of STZ. Meanwhile, in the diabetic treatment group (DM-Water), the weight was reduced than the normal group, but showed a higher weight than the DM group.
STZ 투여는 췌장 내의 β-세포 파괴로 1형 당뇨가 유발되어 인슐린 생성 부족과 그 작용이 저하되며 당대사에 의한 에너지 생산 부족은 성장과 발달에 영향을 준다. 본 실험의 결과에서도 당뇨치료군(DM-water)의 경우 당뇨 유발 후 정상군(NC)에 비해 체중 감소를 보이다가 세리포리아 락세라타 배양액 물 추출물의 첨가로 당대사가 다소 개선되어 체중이 증가한 것으로 추정된다.STZ administration causes
또한, 평균 1일 식이섭취량은 대조군에 비하여 당뇨 실험군(DM, DM-water)에서 증가를 나타내었는데, 이는 당뇨의 증상인 다식, 다뇨, 다갈의 결과인 것으로 보인다. 본 실험에서 정상군(NC)에 비해 당뇨 실험군(DM, DM-water)의 식이 섭취량이 많음에도 불구하고 계속적인 체중감소가 나타났는데, 이는 당뇨에 의한 체내 대사의 퇴행적인 변화 때문인 것으로 보인다.
In addition, the average daily food intake was increased in the diabetic experimental group (DM, DM-water) compared to the control group, which appears to be a result of the symptoms of diabetes, multi-diet, multidose, multidose. Despite the higher dietary intake of the diabetic experimental group (DM, DM-water) compared to the normal group (NC), weight loss continued due to degenerative changes in body metabolism caused by diabetes.
혈당 및 생화학적 분석Blood Sugar and Biochemical Analysis
사육기간 동안의 혈당 변화는 매주 1회 12시간 이상 절식시킨 후 꼬리 정맥의 혈액을 채취하여 혈당측정기(ACCU-CHEK Sensor, Germany)로 측정하였다. 그리고, 2주 간의 사육이 끝난 다음 12시간 절식시킨 rat를 에테르(ether)로 마취시켜 해부하였다. 복부정맥으로부터 헤파린 처리된 주사기로 혈액을 채취하였고, 채혈 후 30분 동안 방치한 뒤 3,000rpm에서 15분간 원심분리하여 혈장을 분리하였다. 분리된 혈장은 액체질소로 급냉시켜 분석시까지 -80℃에 보관하였다. 분리한 혈장은 혈액분석기를 이용하여 혈당, 인슐린, ALT, AST, 총콜레스테롤(TC) 함량을 분석하였다.
Blood glucose changes during the breeding period were fasted for 12 hours or more once a week, and blood was collected from the tail vein and measured with a blood glucose meter (ACCU-CHEK Sensor, Germany). Then, rats fasted for 12 hours after 2 weeks of breeding were anaesthetized with ether. Blood was collected with a heparinized syringe from the abdominal vein, and left for 30 minutes after blood collection, and centrifuged at 3,000 rpm for 15 minutes to separate plasma. The separated plasma was quenched with liquid nitrogen and stored at -80 ° C until analysis. The separated plasma was analyzed for blood glucose, insulin, ALT, AST, total cholesterol (TC) content using a blood analyzer.
혈당 수치 변화를 분석한 결과는 도 2에 나타내었다. NC군에 비해 DM군에서 혈당이 유의적으로 증가하였으며, 시료 투여 전에는 DM군과 DM-Water군 간의 차이를 보이지 않다가, 실시예 2의 추출물을 첨가한 1주 후부터 DM 군에 비해 혈당 수치가 유의적으로 감소하였다. 시료 투여 2주째에는 DM 군에 비해 DM-water 군의 혈당이 유의적으로 크게 감소되었다. DM군은 STZ을 복강 주사하여 췌장의 파괴로 인슐린 분비가 억제되어 대조군에 비해 혈당이 월등히 높게 나타났고, 반면 DM-water 군은 실시예 2의 추출물 투여로 인해 혈당이 감소된 것으로 보인다.
The results of analyzing blood glucose level changes are shown in FIG. 2. The blood glucose level was significantly increased in the DM group compared to the NC group, and there was no difference between the DM group and the DM-Water group before the administration of the sample, but the blood glucose level was higher than the DM group one week after the addition of the extract of Example 2 Significantly decreased. At 2 weeks after the administration of the sample, the blood glucose of the DM-water group was significantly decreased compared to the DM group. DM group was intraperitoneally injected with STZ to inhibit insulin secretion due to pancreatic destruction, resulting in significantly higher blood glucose than the control group, whereas DM-water group appeared to have reduced blood glucose due to the administration of the extract of Example 2.
혈액 내 ALT 및 AST의 활성변화를 관찰한 결과, NC 군에 비해 DM 군에서 이들 효소 활성이 증가되었다가 실시예 2의 추출물을 첨가한 군에서는 ALT 및 AST의 활성이 감소되었다. 즉, ALT 및 AST는 약물에 의해 간내 손상이 생기면 이들 활성이 증가되는 효소로 알려져 있는데, STZ 투여로 증가된 이들 효소 활성이 실시예 2의 추출물의 첨가로 활성이 감소되는 것으로 보아 실시예 2의 추출물은 STZ로 인한 간내 손상을 다소 개선시키는 것을 알 수 있다.As a result of observing changes in the activity of ALT and AST in the blood, the enzyme activity was increased in the DM group compared to the NC group, but the activity of ALT and AST was decreased in the group to which the extract of Example 2 was added. In other words, ALT and AST are known to be enzymes that increase their activity when hepatic damage caused by drugs, the activity of these enzymes increased by the addition of the extract of Example 2 is reduced by the addition of the extract of Example 2 The extract can be seen to somewhat improve the liver damage caused by STZ.
혈장 내 총콜레스테롤 농도의 경우, NC군에 비해 DM군에서 증가하였다가, 실시예 2의 추출물 첨가로 혈장 콜레스테롤 농도가 DM군에 비해 감소하였다. 당뇨 유발군에서 총 콜레스테롤치가 증가하는 것은 당뇨가 유발된 흰쥐의 대사에 있어서 탄수화물이 에너지원으로 이용되지 못하고, 유리지방산이 에너지로 이용되면서 콜레스테롤을 합성하기 때문이라고 추정된다.Plasma total cholesterol concentration was increased in DM group compared to NC group, but plasma cholesterol concentration was decreased compared to DM group by the addition of the extract of Example 2. The increase in total cholesterol in the diabetic group is presumed to be due to carbohydrates not being used as an energy source in metabolism of diabetic rats, but because free fatty acids are used as energy to synthesize cholesterol.
그리고, 혈장내 중성지질 농도도 NC군에 비해 DM군에서 증가하였다가, DM-Water 군에서는 중성지질 함량이 감소하였다. 당뇨병의 주된 합병증 중 하나인 고지혈증의 경우, 정상보다 혈장 내 지방산이 중성지방으로 전환되는 속도가 증가하여 혈장내 중성지방 농도가 높아진다고 알려져 있다. 본 실험에서도 당뇨 시 중성지질 농도가 증가됨이 일치하였으며, 실시예 2의 추출물 첨가 시 혈장 중성지질 농도가 감소되어 당뇨 쥐의 지질대사 개선에 관여하는 것으로 사료된다.
In addition, the plasma triglyceride concentration was increased in the DM group compared with the NC group, but the neutral lipid content was decreased in the DM-Water group. Hyperlipidemia, one of the main complications of diabetes, is known to increase plasma triglyceride levels by increasing the rate of fatty acid conversion to triglycerides than normal. In this experiment, the concentration of triglycerides in diabetic was consistently increased, and the concentration of triglycerides in plasma was decreased when the extract of Example 2 was added.
실험예Experimental Example 4: 지표 물질 분석 4: Indicator Material Analysis
LC/MS/MS는 Agilent Technologies Agilent 6410를 사용하였으며 Ion souce는 negative로 하고 fragmentor은 150으로하여 분석하였다. Gas 온도는 320℃, gas flow는 분당 35 mL의 속도로 흘려주며 분석하였고 capillary volt는 4000으로 하여 분석하였다. HPLC의 컬럼은 Epic C18을 사용하였고 컬럼의 온도는 40℃로 유지하였다. 이동상으로는 0.1% formic acid를 포함한 증류수(A)와 0.1% formic acid를 함유한 아세토니트릴(acetonitrile)(B)를 사용하였다. 이동상의 gradient 조건은 아래 표 5와 같다. 시료 300mg를 취하여 80wt% 메탄올 2.0mL을 주입하여 10분간 sonication 후 0.45um membrane filter를 통과시킨 용액을 20uL 주입하였다.
LC / MS / MS was analyzed using Agilent Technologies Agilent 6410 with ion souce negative and
최근 항당뇨 효능이 있다고 알려진 대표적인 지표 물질 3가지(프로토카테추알데히드(Protocatechualdehyde),2,5-디하이드록시벤조산(2,5-dihydroxybenzoic acid), 2,5-디하이드록시아세토페논(2,5-dihydroxyacetophenone))를 LC/MS/MS를 이용하여 정량한 결과는 하기 표 6과 같다. 특히, 당뇨병 치료에 탁월한 효과가 있다고 알려진 프로토카테추알데히드(Protocatechualdehyde)는 실시예 2의 추출물에 1g당 18.79㎍이 함유되어 있는 것으로 나타났다.
Three representative indicators known to have antidiabetic effects (protocatechualdehyde), 2,5-dihydroxybenzoic acid, and 2,5-dihydroxyacetophenone (2, 5-dihydroxyacetophenone)) was quantified using LC / MS / MS as shown in Table 6 below. In particular, protocatechualdehyde, which is known to have an excellent effect on the treatment of diabetes, was found to contain 18.79 μg per gram of the extract of Example 2.
상기 살펴본 바와 같이, 본 발명에 따르면 당뇨병 치료에 탁월한 효과가 있다고 알려진 프로토카테추알데히드가 최소 10㎍/g 이상 포함된 세리포리아 락세라타 배양액 추출물을 제공할 수 있으며, 구체적으로는 프로토카테추알데히드가 10~25㎍/g의 양으로 포함된 세리포리아 락세라타 배양액 추출물을 제공할 수 있다.As it discussed above, according to the present invention and the prototype catheter weight aldehydes known to be an excellent effect on the treatment of diabetes can provide three Syrian lipoic lock Sera other culture extract containing at least 10㎍ / g or more, specifically, the category estimation protocol and aged between 10 and aldehyde in an amount of 25㎍ / g lipoic Ria is possible to provide a lock Sera other culture extract.
Claims (13)
(S2) 세리포리아 락세라타 균사체 배양액을 동결 건조시켜 분말화하는 단계; 및
(S3) 세리포리아 락세라타 균사체 배양액 분말을 물, 에탄올, 메탄올, 아세톤, 부탄올 및 에틸아세테이트로 이루어진 군에서 선택된 1종의 용매 또는 2종 이상의 혼합용매로 추출한 후 이를 여과하고 감압농축하는 단계;를 포함하는 세리포리아 락세라타 배양액 추출물의 제조방법.
(S1) three other repositories Ria Rock Serra (Ceriporia the mycelium of lacerata) preparing a three reports Ria lock Sera other mycelium culture liquid by liquid culture;
(S2) comprising: a powdered freeze-dried three reports Ria lock Sera other mycelium culture liquid; And
(S3) the three reports Ria lock sera extract the other mycelium broth powder with water, ethanol, methanol, acetone, butanol and ethyl acetate, one solvent or two or mixture of two or more solvents selected from the group consisting of the steps of filtered and concentrated under reduced pressure the method of the three repositories Ria Rock Serra another culture medium containing the extract;
(S1) 단계에서의 액체배양은 20℃~30℃에서 5~16일간 수행되는 것인 세리포리아 락세라타 배양액 추출물의 제조방법.
The method of claim 1,
(S1) phase liquid culture method of manufacturing a three reports Ria lock Sera other broth extract is performed 5-16 days at 20 ℃ ~ 30 ℃ in.
(S1) 단계에서의 액체배양은 1~3 vvm(공기 부피/배지 부피/분)의 공기를 주입하며 수행되는 것인 세리포리아 락세라타 배양액 추출물의 제조방법.
The method of claim 1,
(S1) phase liquid culture is 1 ~ 3 vvm of injecting air (air volume / volume of medium / minute) and the method of manufacturing a three reports Ria lock Sera other broth extract is performed in.
(S1) 단계에서의 액체배양을 위한 배지 조성물은 포도당 0.2~3중량%, 설탕 0.2~3중량%, 전분 0.2~4중량%, 대두분 0.2~3중량%, 황산마그네슘(MgSO4)0.05~0.1중량%, 인산이수소칼륨(KH2PO4) 0.05~0.1중량% 및 물 90~99중량%를 포함하는 것인 세리포리아 락세라타 배양액 추출물의 제조방법.
The method of claim 1,
Medium composition for liquid culture in step (S1) is 0.2 to 3% by weight of glucose, 0.2 to 3% by weight of sugar, 0.2 to 4% by weight of starch, 0.2 to 3% by weight of soy flour, magnesium sulfate (MgSO 4 ) 0.05 ~ 0.1 wt.%, potassium dihydrogen phosphate (KH 2 PO 4) 0.05 ~ 0.1 the method of producing a three reports Ria lock Sera other culture extract comprises wt% and water 90 to 99% by weight.
(S2) 단계에서의 동결건조는 20℃~30℃에서 48시간~72시간 동안 수행되는 것인 세리포리아 락세라타 배양액 추출물의 제조방법.
The method of claim 1,
(S2) phase is freeze-dried Method of manufacturing a three reports Ria lock Sera other broth extract is performed for from 20 ℃ ~ 30 ℃ 48 sigan ~ 72 hours at.
(S3) 단계에서의 용매는 물 또는 50%(w/w)~80%(w/w)의 에탄올 수용액인 것을 특징으로 하는 세리포리아 락세라타 배양액 추출물의 제조방법.
The method of claim 1,
Solvent in (S3) step is the production of three reports Ria lock Sera other culture extract, characterized in that the aqueous ethanol solution in water or 50% (w / w) ~ 80% (w / w).
(S3) 단계에서의 추출은 세리포리아 락세라타 균사체 분말에 대하여 20~50mL/g의 용매를 첨가하여 수행되는 것인 세리포리아 락세라타 배양액 추출물의 제조방법.
The method of claim 1,
Extraction in (S3) is phase process for producing a three reports Ria lock sera of three other reports RIA is performed by adding a solvent of 20 ~ 50mL / g with respect to the mycelium powder lock Sera other culture extract.
(S3) 단계에서의 추출은 20℃~30℃에서 5~7시간 동안 수행되는 것인 세리포리아 락세라타 배양액 추출물의 제조방법.
The method of claim 1,
(S3) is phase extraction method for producing a three reports Ria lock Sera other broth extract is performed for 5 to 7 hours at 20 ℃ ~ 30 ℃ in.
Any one of claims 1 to 8 prepared in the three reports Ria any one of the production method of the anti-lock Sera other culture extract.
프로토카테추알데히드(Protocatechualdehyde)를 10~25㎍/g 포함하는 것을 특징으로 하는 세리포리아 락세라타 배양액 추출물.
10. The method of claim 9,
Three lipoic Ria lock Sera other culture extract comprising the protocol category weight aldehydes (Protocatechualdehyde) 10 ~ 25㎍ / g .
프로토카테추알데히드(Protocatechualdehyde)를 17~25㎍/g 포함하는 것을 특징으로 하는 세리포리아 락세라타 배양액 추출물.
10. The method of claim 9,
Three lipoic Ria lock Sera other culture extract comprising the protocol category weight aldehydes (Protocatechualdehyde) 17 ~ 25㎍ / g .
Section 9-year-old Ria Repo Rock Serra another culture extracts pharmaceutical composition for the treatment and prevention of diseases, including diabetes.
The three repositories paragraph 9 Leah supplements containing the extract of Rock Serra another culture.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100112236A KR101031605B1 (en) | 2010-11-11 | 2010-11-11 | Manufacturing method of culture extract of ceriporia lacerata for the therapy of diabetic diseases and culture extract of ceriporia lacerata using the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100112236A KR101031605B1 (en) | 2010-11-11 | 2010-11-11 | Manufacturing method of culture extract of ceriporia lacerata for the therapy of diabetic diseases and culture extract of ceriporia lacerata using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101031605B1 true KR101031605B1 (en) | 2011-04-27 |
Family
ID=44050678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100112236A KR101031605B1 (en) | 2010-11-11 | 2010-11-11 | Manufacturing method of culture extract of ceriporia lacerata for the therapy of diabetic diseases and culture extract of ceriporia lacerata using the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101031605B1 (en) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102807956A (en) * | 2012-07-12 | 2012-12-05 | 华东理工大学 | Ceriporia lacerata strain and application thereof |
CN103173357A (en) * | 2011-12-22 | 2013-06-26 | 高冬 | Ceriporia lacerata and application thereof |
US20140193455A1 (en) * | 2013-01-09 | 2014-07-10 | Byoung Cheon KIM | Pharmaceutical composition for prevention or treatment of steroid-induced diabetes and health functional food |
US20140193454A1 (en) * | 2013-01-09 | 2014-07-10 | Byoung Cheon KIM | Method from preparing ceriporia lacerata culture extract and pharmaceutical composition for prevention or treatment of diabetes and diabetic complications comprising ceriporia lacerata culture extract as active ingredient |
WO2014112666A1 (en) * | 2013-01-18 | 2014-07-24 | (주) 퓨젠바이오농업회사법인 | Method for preparing extract from culture medium of ceriporia lacerata and pharmaceutical composition prepared thereby for preventing or treating diabetic diseases and diabetic complications, which contains extract from culture medium of ceriporia lacerata as active ingredient |
WO2014112665A1 (en) * | 2013-01-18 | 2014-07-24 | (주)월드바이오텍 | Pharmaceutical composition and health functional food for preventing or treating steroid-induced diabetes |
KR101444614B1 (en) | 2013-08-01 | 2014-09-26 | 계명대학교 산학협력단 | Method for producing fermented material with high GABA by mixed culture of Ceriporia lacerata and Lactobacillus |
WO2016010182A1 (en) * | 2014-07-14 | 2016-01-21 | (주)퓨젠바이오농업회사법인 | Composition for improving liver function comprising as active ingredient exopolysaccharide derived from extract from culture medium of ceriporia lacerata |
WO2016010183A1 (en) * | 2014-07-14 | 2016-01-21 | (주)퓨젠바이오농업회사법인 | Composition for improving lipid-related metabolism comprising as active ingredient exopolysaccharide derived from extract from culture medium of ceriporia lacerata |
KR20160051468A (en) * | 2014-11-03 | 2016-05-11 | (주)퓨젠바이오농업회사법인 | Sexual function improvement composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR20160051465A (en) * | 2014-11-03 | 2016-05-11 | (주)퓨젠바이오농업회사법인 | Tranquilizer composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
WO2016072697A1 (en) * | 2014-11-03 | 2016-05-12 | (주)퓨젠바이오농업회사법인 | Blood pressure lowering composition containing as active ingredient exopolysaccharide produced by means of ceriporia lacerata |
WO2016085290A1 (en) * | 2014-11-27 | 2016-06-02 | (주)퓨젠바이오농업회사법인 | Antioxidant composition containing extracellular polysaccharide produced using ceriporia lacerata as active ingredient |
KR20160094332A (en) | 2015-01-30 | 2016-08-09 | (주)퓨젠바이오농업회사법인 | Pharmaceutical composition for the prevention or treatment of a cancer comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101655882B1 (en) | 2015-10-08 | 2016-09-08 | (주)퓨젠바이오농업회사법인 | Composition for eliminating hangover comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101655878B1 (en) | 2015-10-08 | 2016-09-08 | (주)퓨젠바이오농업회사법인 | Composition for preventing hair loss and enhancing hair growth comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101682104B1 (en) | 2015-11-26 | 2016-12-02 | (주)퓨젠바이오농업회사법인 | Composition for kidney protection comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101682101B1 (en) | 2015-11-26 | 2016-12-02 | (주)퓨젠바이오농업회사법인 | Composition for skin protection against uv comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101682108B1 (en) | 2015-10-08 | 2016-12-02 | (주)퓨젠바이오농업회사법인 | Composition for blood flow improvement comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101691975B1 (en) | 2016-02-16 | 2017-01-02 | (주)퓨젠바이오농업회사법인 | Pharmaceutical composition for the prevention or treatment of neurodegenerative brain diseases comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
CN106318876A (en) * | 2015-07-07 | 2017-01-11 | 中国科学院天津工业生物技术研究所 | Ceriporia lacerata strain and culture method and application thereof |
JP2017025327A (en) * | 2016-09-07 | 2017-02-02 | ヒュジェンバイオ シーオー.,エルティーディー | Preparation method of ceriporia-lacerata culture liquid extract and pharmaceutical composition for preventing or treating diabetic diseases and diabetic complications containing ceriporia-lacerata culture liquid extract prepared thereby as active ingredient |
WO2017023070A1 (en) * | 2015-08-06 | 2017-02-09 | (주)퓨젠바이오농업회사법인 | Composition for promoting fatigue recovery containing, as an active ingredient, extracellular polysaccharides produced by ceriporia lacerate |
WO2017026697A1 (en) * | 2015-08-12 | 2017-02-16 | (주)퓨젠바이오농업회사법인 | Composition containing extracellular polysaccharide produced by ceriporia lacerata as active ingredient for immunoregulation |
KR20170020389A (en) | 2015-08-12 | 2017-02-22 | (주)퓨젠바이오농업회사법인 | Composition for immunosuppression comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR20170020124A (en) | 2015-08-13 | 2017-02-22 | (주)퓨젠바이오농업회사법인 | Composition for improving skin condition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101723402B1 (en) | 2016-12-23 | 2017-04-05 | 한상선 | Method of preparing compositioni containing active ingredient of culture medium of ceriporia lacerata for prevention and improvement of diabetes, diabetic complications disease from diabetes |
KR101853429B1 (en) | 2017-09-21 | 2018-04-30 | 김영호 | Mutant of Ceriporia lacerata and preparing method thereof |
KR101853428B1 (en) | 2017-09-21 | 2018-04-30 | 김영호 | Mutant of Ceriporia lacerata and preparing method thereof |
KR101900426B1 (en) | 2017-03-17 | 2018-09-20 | (주)퓨젠바이오 | Pharmaceutical composition for the prevention or treatment of obesity comprising culture medium of ceriporia lacerata |
KR101925890B1 (en) | 2018-08-02 | 2018-12-06 | 김병천 | Novel strain of Ceriporia lacerata-K1, and composition comprising its culture for preventing or treating diabetes mellitus |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007252972A (en) | 2006-03-20 | 2007-10-04 | Idemitsu Kosan Co Ltd | Cleaning method for petroleum-contaminated soil |
JP2008245629A (en) | 2007-03-30 | 2008-10-16 | Kyushu Univ | Microbial preparation for treatment of woody waste |
-
2010
- 2010-11-11 KR KR1020100112236A patent/KR101031605B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007252972A (en) | 2006-03-20 | 2007-10-04 | Idemitsu Kosan Co Ltd | Cleaning method for petroleum-contaminated soil |
JP2008245629A (en) | 2007-03-30 | 2008-10-16 | Kyushu Univ | Microbial preparation for treatment of woody waste |
Non-Patent Citations (2)
Title |
---|
LEE, J.-W., J. Microbiol.(2007) Vol.45, No.6, pp.485-491. |
박준영, 서울대학교대학원 석사학위논문(2007) |
Cited By (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103173357A (en) * | 2011-12-22 | 2013-06-26 | 高冬 | Ceriporia lacerata and application thereof |
CN102807956A (en) * | 2012-07-12 | 2012-12-05 | 华东理工大学 | Ceriporia lacerata strain and application thereof |
US20140193455A1 (en) * | 2013-01-09 | 2014-07-10 | Byoung Cheon KIM | Pharmaceutical composition for prevention or treatment of steroid-induced diabetes and health functional food |
US20140193454A1 (en) * | 2013-01-09 | 2014-07-10 | Byoung Cheon KIM | Method from preparing ceriporia lacerata culture extract and pharmaceutical composition for prevention or treatment of diabetes and diabetic complications comprising ceriporia lacerata culture extract as active ingredient |
GB2529557A (en) * | 2013-01-18 | 2016-02-24 | Fugenbio Co Ltd | Method for preparing extract from culture medium of ceriporia lacerata and pharmaceutical composition prepared thereby for preventing or treating diabetic |
WO2014112666A1 (en) * | 2013-01-18 | 2014-07-24 | (주) 퓨젠바이오농업회사법인 | Method for preparing extract from culture medium of ceriporia lacerata and pharmaceutical composition prepared thereby for preventing or treating diabetic diseases and diabetic complications, which contains extract from culture medium of ceriporia lacerata as active ingredient |
WO2014112665A1 (en) * | 2013-01-18 | 2014-07-24 | (주)월드바이오텍 | Pharmaceutical composition and health functional food for preventing or treating steroid-induced diabetes |
CN105142655A (en) * | 2013-01-18 | 2015-12-09 | 首尔福建生物有限会社 | Method for preparing extract from culture medium of ceriporia lacerata and pharmaceutical composition prepared thereby for preventing or treating diabetic diseases and diabetic complications, which contains extract from culture medium of ceriporia lacerata as active ingredient |
AU2013374516B2 (en) * | 2013-01-18 | 2017-02-02 | Fugenbiopharma Co., Ltd. | Method for preparing extract from culture medium of Ceriporia lacerata and pharmaceutical composition prepared thereby for preventing or treating diabetic diseases and diabetic complications, which contains extract from culture medium of Ceriporia lacerata as active ingredient |
JP2016506719A (en) * | 2013-01-18 | 2016-03-07 | ヒュジェンバイオ シーオー.,エルティーディー | Preparation method of culture liquid extract of Serlipria racerata and pharmaceutical composition for prevention or treatment of diabetic diseases and diabetic complications containing culture liquid extract of serlipria racerata prepared therefrom as an active ingredient |
KR101444614B1 (en) | 2013-08-01 | 2014-09-26 | 계명대학교 산학협력단 | Method for producing fermented material with high GABA by mixed culture of Ceriporia lacerata and Lactobacillus |
KR20160008431A (en) | 2014-07-14 | 2016-01-22 | (주)퓨젠바이오농업회사법인 | Composition for improvement of lipid-related metabolic function comprising exopolysaccharide derived from ceriporia lacerata culture broth extracts as an active ingredient |
KR20160008425A (en) | 2014-07-14 | 2016-01-22 | (주)퓨젠바이오농업회사법인 | Composition for improvement of liver function comprising exopolysaccharide derived from ceriporia lacerata culture broth extracts as an active ingredient |
WO2016010183A1 (en) * | 2014-07-14 | 2016-01-21 | (주)퓨젠바이오농업회사법인 | Composition for improving lipid-related metabolism comprising as active ingredient exopolysaccharide derived from extract from culture medium of ceriporia lacerata |
WO2016010182A1 (en) * | 2014-07-14 | 2016-01-21 | (주)퓨젠바이오농업회사법인 | Composition for improving liver function comprising as active ingredient exopolysaccharide derived from extract from culture medium of ceriporia lacerata |
KR20160051468A (en) * | 2014-11-03 | 2016-05-11 | (주)퓨젠바이오농업회사법인 | Sexual function improvement composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
US9950022B2 (en) | 2014-11-03 | 2018-04-24 | Fugenbio Co., Ltd. | Sexual function improving composition containing as active ingredient exopolysaccharide produced by means of ceriporia lacerata |
WO2016072713A1 (en) * | 2014-11-03 | 2016-05-12 | (주)퓨젠바이오농업회사법인 | Sexual function improving composition containing as active ingredient exopolysaccharide produced by means of ceriporia lacerata |
WO2016072697A1 (en) * | 2014-11-03 | 2016-05-12 | (주)퓨젠바이오농업회사법인 | Blood pressure lowering composition containing as active ingredient exopolysaccharide produced by means of ceriporia lacerata |
KR20160051465A (en) * | 2014-11-03 | 2016-05-11 | (주)퓨젠바이오농업회사법인 | Tranquilizer composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101645652B1 (en) | 2014-11-03 | 2016-08-08 | (주)퓨젠바이오농업회사법인 | Sexual function improvement composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
CN107001487A (en) * | 2014-11-03 | 2017-08-01 | 福健生物技术有限公司 | Contain the exocellular polysaccharide generated by tear wax pore fungi as active ingredient for improving the composition of sexual function |
CN108463123B (en) * | 2014-11-03 | 2021-12-03 | 福健生物制药有限公司 | Composition for lowering blood pressure containing exopolysaccharide produced by Ceriporia lacerata as effective component |
KR101682096B1 (en) | 2014-11-03 | 2016-12-02 | (주)퓨젠바이오농업회사법인 | Tranquilizer composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
CN108463123A (en) * | 2014-11-03 | 2018-08-28 | 福健生物制药有限公司 | Contain composition for blood pressure lowering of the exocellular polysaccharide generated by tearing wax pore fungi as active ingredient |
WO2016072710A1 (en) * | 2014-11-03 | 2016-05-12 | (주)퓨젠바이오농업회사법인 | Tranquilizing composition containing as active ingredient exopolysaccharide produced by means of ceriporia lacerata |
CN106998777A (en) * | 2014-11-03 | 2017-08-01 | 福健生物制药有限公司 | Contain by tear wax pore fungi generate exocellular polysaccharide as active ingredient the composition for calming nerves |
US10226494B2 (en) | 2014-11-27 | 2019-03-12 | Fugenbio Co., Ltd. | Antioxidant composition containing extracellular polysaccharide produced using Ceriporia lacerata as active ingredient |
WO2016085290A1 (en) * | 2014-11-27 | 2016-06-02 | (주)퓨젠바이오농업회사법인 | Antioxidant composition containing extracellular polysaccharide produced using ceriporia lacerata as active ingredient |
KR101737627B1 (en) | 2014-11-27 | 2017-05-19 | (주)퓨젠바이오 | Antioxidant composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR20160094332A (en) | 2015-01-30 | 2016-08-09 | (주)퓨젠바이오농업회사법인 | Pharmaceutical composition for the prevention or treatment of a cancer comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
CN106318876A (en) * | 2015-07-07 | 2017-01-11 | 中国科学院天津工业生物技术研究所 | Ceriporia lacerata strain and culture method and application thereof |
KR20170017425A (en) | 2015-08-06 | 2017-02-15 | (주)퓨젠바이오농업회사법인 | Composition for relieving fatigue comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101712590B1 (en) | 2015-08-06 | 2017-03-07 | (주)퓨젠바이오농업회사법인 | Composition for relieving fatigue comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
WO2017023070A1 (en) * | 2015-08-06 | 2017-02-09 | (주)퓨젠바이오농업회사법인 | Composition for promoting fatigue recovery containing, as an active ingredient, extracellular polysaccharides produced by ceriporia lacerate |
US10772920B2 (en) | 2015-08-12 | 2020-09-15 | Fugenbio Co., Ltd. | Composition containing extracellular polysaccharide produced by ceriporia lacerata as active ingredient for immunoregulation |
WO2017026697A1 (en) * | 2015-08-12 | 2017-02-16 | (주)퓨젠바이오농업회사법인 | Composition containing extracellular polysaccharide produced by ceriporia lacerata as active ingredient for immunoregulation |
KR20170020389A (en) | 2015-08-12 | 2017-02-22 | (주)퓨젠바이오농업회사법인 | Composition for immunosuppression comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR20170020218A (en) | 2015-08-12 | 2017-02-22 | (주)퓨젠바이오농업회사법인 | Composition for immunomodulation comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR20170020124A (en) | 2015-08-13 | 2017-02-22 | (주)퓨젠바이오농업회사법인 | Composition for improving skin condition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
WO2017061787A1 (en) * | 2015-10-08 | 2017-04-13 | (주)퓨젠바이오농업회사법인 | Composition for relieving hangovers containing extracellular polysaccharide produced from ceriporia lacerata as active ingredient |
WO2017061769A1 (en) * | 2015-10-08 | 2017-04-13 | (주)퓨젠바이오농업회사법인 | Composition for preventing alopecia or stimulating hair growth containing extracellular polysaccharide produced from ceriporia lacerata as active ingredient |
WO2017061819A1 (en) * | 2015-10-08 | 2017-04-13 | (주)퓨젠바이오농업회사법인 | Composition for improving blood circulation containing extracellular polysaccharide produced from ceriporia lacerata as active ingredient |
CN108135951A (en) * | 2015-10-08 | 2018-06-08 | 福健生物技术有限公司 | Contain by the exocellular polysaccharide that tear wax pore fungi generates as active ingredient for anti-alopecia-stopping or the composition of promotion hair tonic |
US10617730B2 (en) | 2015-10-08 | 2020-04-14 | Fugenbio Co., Ltd. | Composition for preventing alopecia or stimulating hair growth containing extracellular polysaccharide produced from ceriporia lacerata as active ingredient |
KR101682108B1 (en) | 2015-10-08 | 2016-12-02 | (주)퓨젠바이오농업회사법인 | Composition for blood flow improvement comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101655878B1 (en) | 2015-10-08 | 2016-09-08 | (주)퓨젠바이오농업회사법인 | Composition for preventing hair loss and enhancing hair growth comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101655882B1 (en) | 2015-10-08 | 2016-09-08 | (주)퓨젠바이오농업회사법인 | Composition for eliminating hangover comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101682104B1 (en) | 2015-11-26 | 2016-12-02 | (주)퓨젠바이오농업회사법인 | Composition for kidney protection comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101682101B1 (en) | 2015-11-26 | 2016-12-02 | (주)퓨젠바이오농업회사법인 | Composition for skin protection against uv comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101691975B1 (en) | 2016-02-16 | 2017-01-02 | (주)퓨젠바이오농업회사법인 | Pharmaceutical composition for the prevention or treatment of neurodegenerative brain diseases comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
JP2017025327A (en) * | 2016-09-07 | 2017-02-02 | ヒュジェンバイオ シーオー.,エルティーディー | Preparation method of ceriporia-lacerata culture liquid extract and pharmaceutical composition for preventing or treating diabetic diseases and diabetic complications containing ceriporia-lacerata culture liquid extract prepared thereby as active ingredient |
KR101723402B1 (en) | 2016-12-23 | 2017-04-05 | 한상선 | Method of preparing compositioni containing active ingredient of culture medium of ceriporia lacerata for prevention and improvement of diabetes, diabetic complications disease from diabetes |
KR101900426B1 (en) | 2017-03-17 | 2018-09-20 | (주)퓨젠바이오 | Pharmaceutical composition for the prevention or treatment of obesity comprising culture medium of ceriporia lacerata |
KR101853428B1 (en) | 2017-09-21 | 2018-04-30 | 김영호 | Mutant of Ceriporia lacerata and preparing method thereof |
KR101853429B1 (en) | 2017-09-21 | 2018-04-30 | 김영호 | Mutant of Ceriporia lacerata and preparing method thereof |
KR101925890B1 (en) | 2018-08-02 | 2018-12-06 | 김병천 | Novel strain of Ceriporia lacerata-K1, and composition comprising its culture for preventing or treating diabetes mellitus |
WO2020027456A1 (en) * | 2018-08-02 | 2020-02-06 | 김병천 | Novel ceriporia laccerata-k1 strain and composition comprising a culture thereof as effective ingredient for preventing or treating diabetes |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101031605B1 (en) | Manufacturing method of culture extract of ceriporia lacerata for the therapy of diabetic diseases and culture extract of ceriporia lacerata using the same | |
Ohaeri | Effect of garlic oil on the levels of various enzymes in the serum and tissue of streptozotocin diabetic rats | |
Lo et al. | Effects of ingested fruiting bodies, submerged culture biomass, and acidic polysaccharide glucuronoxylomannan of Tremella mesenterica Retz.: Fr. on glycemic responses in normal and diabetic rats | |
CN111096983A (en) | Phellinus igniarius phenolic extract with hypoglycemic activity and preparation and application thereof | |
Rao et al. | Insulin stimulative and anti-oxidative effects of Persea americana fruit extract on streptozotocin induced hyperglycemic rats | |
JP4602674B2 (en) | Maltase inhibitor | |
KR101270599B1 (en) | Fermented red ginseng composition containing fermented red ginseng and medical plant extracts exhibiting antidiabetic activity | |
CN111867402A (en) | Agaricus campestris composite mycelium composition with liver function improving activity and its preparation method | |
KR20200032007A (en) | Pharmaceutical composition comprising extract of fermented ginger for prevention or treatment of metabolic disease | |
KR20080079962A (en) | Hypoglycemic exopolysaccharides from tremella fuciformis mycellium and a preparation method thereof | |
KR100963511B1 (en) | Exopolysaccharides for type 2 diabetes therapy from Phellinus baumii mycellium and a preparation method thereof | |
Watanabe et al. | Pharmacological investigation of Ceraceomyces tessulatus (Agaricomycetes) in mice with nonalcoholic steatohepatitis | |
US8273388B2 (en) | Extract of Polygonum multiflorum Thunb. ex Murray var. hypoleucum and compositions for improving metabolic syndrome | |
KR20080114456A (en) | Anti-diabetic composition using rhodiola rosea | |
Elkhateeb et al. | The Anti-Diabetic Potential Of Mushrooms: A Review | |
CN115998838B (en) | Composition with blood sugar reducing synergistic effect and application thereof | |
KR100547169B1 (en) | A composition containing fermented Inonotus Obliquus for preventing and treating diabetes | |
KR100781817B1 (en) | Freeze Dryed Material, Ethanol Precipitates, Ethylacetate Fraction of Agaricus Blazei Mushroom Mycelia and Manufacturing Process Thereof | |
Nurul Azwa | Characterization of potential anti-diabetic related-proteins from Pleurotus Pulmonarius (Fr.) Quel.(grey oyster mushroom)/Nurul Azwa Abd Wahab | |
WO2007091827A1 (en) | Extract from submerged culture of fomitopsis pinicola mycelia and hypoglycemic composition comprising the same | |
KR100583073B1 (en) | A composition for treating diabetes comprising freeze-dried products from a submerged mycelial culture of Elfvingia applanata as an effective ingredient | |
KR20230057134A (en) | A composition for postprandial anti-hyperglycemia comprising Nipa Fruticans Wurmb extract | |
KR20140041627A (en) | Extract from salted and fermented shrimp, manufacturing method of the same and composition containing the same | |
CN110742901A (en) | Metabolism check point FBP1 agonist and application thereof in anti-tumor aspect | |
Puri et al. | Investigations on Screening of Endophytic Fungal Fractions of Andrographis Paniculata (Burm. F.) Wall Nees. Leaves in Paracetamol and Ethanol Induced Hepatotoxicity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140407 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20160411 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170410 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20190327 Year of fee payment: 9 |